![20.3 [TAb 250]](/static/images/cells-no_picture.jpg)
-
平臺編號：bio-68794
-
國際編號：CRL-2655?
-
細(xì)胞信息： 20.3 [TAb 250]
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
20.3 [TAb 250]
ATCC Number：CRL-2655?
是否是腫瘤細(xì)胞：0
物種來源：小鼠
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1; kappa light chain
運輸方式：凍存運輸
生長狀態(tài)：懸浮生長
數(shù)量：大量
規(guī)格：0.5ml Designations: 20.3 [TAb 250]
Depositors: ?Berlex Laboratories, Inc.
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: lymphocyte
Cellular Products:immunoglobulin; monoclonal antibody; against human c-erb B2 protein
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with NIH3T3 cells transfected with the human c-erb B2 oncogene.
Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells.
The hybridoma cell line named 20.3 produces monoclonal antibody TAb 250. [53337 ]
The TAb 250 monoclonal antibody is specific for an extracellular epitope of the c-erbB-2 protein (gp185). It inhibits in a dose-dependent manner the in vitro proliferation of human breast tumor cell lines that overexpress c-erbB-2. [56131 ]
A culture deposited with the ATCC as HB-10646 in January of 1991 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline.
The cured cell line is available as CRL-2655. The original patent deposit is available as HB-10646.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
parental cell line:ATCC HB-10646
References: 53337: Shawver LK, et al. Anti-neoplastic drugs in cancer therapy. US Patent 6,123,939 dated Sep 26 2000
56131: Hancock MC, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity. Cancer Res. 51: 4575-4580, 1991. PubMed: 1678683
是否是腫瘤細(xì)胞：0
物種來源：小鼠
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1; kappa light chain
運輸方式：凍存運輸
生長狀態(tài)：懸浮生長
數(shù)量：大量
規(guī)格：0.5ml Designations: 20.3 [TAb 250]
Depositors: ?Berlex Laboratories, Inc.
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: lymphocyte
Cellular Products:immunoglobulin; monoclonal antibody; against human c-erb B2 protein
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with NIH3T3 cells transfected with the human c-erb B2 oncogene.
Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells.
The hybridoma cell line named 20.3 produces monoclonal antibody TAb 250. [53337 ]
The TAb 250 monoclonal antibody is specific for an extracellular epitope of the c-erbB-2 protein (gp185). It inhibits in a dose-dependent manner the in vitro proliferation of human breast tumor cell lines that overexpress c-erbB-2. [56131 ]
A culture deposited with the ATCC as HB-10646 in January of 1991 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline.
The cured cell line is available as CRL-2655. The original patent deposit is available as HB-10646.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
parental cell line:ATCC HB-10646
References: 53337: Shawver LK, et al. Anti-neoplastic drugs in cancer therapy. US Patent 6,123,939 dated Sep 26 2000
56131: Hancock MC, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity. Cancer Res. 51: 4575-4580, 1991. PubMed: 1678683
